This is a StreetInsider.com Premium Only Page

(INZY) – Company Press Releases

Apr 8, 2024 06:30 AM Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Apr 5, 2024 06:00 PM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2024 08:30 AM Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024 08:30 AM Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Mar 12, 2024 08:30 AM Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Feb 26, 2024 08:30 AM Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024 08:30 AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2023 08:30 AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 9, 2023 08:30 AM Inozyme Pharma to Participate in Upcoming Investor Conferences

Nov 7, 2023 08:30 AM Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 3, 2023 04:15 PM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 26, 2023 08:30 AM Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

Oct 10, 2023 08:30 AM Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

Oct 6, 2023 08:30 AM Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Sep 26, 2023 07:30 AM Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Sep 20, 2023 08:30 AM Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Sep 6, 2023 08:30 AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2023 08:30 AM Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 8, 2023 08:30 AM Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Aug 3, 2023 04:01 PM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2023 04:01 PM Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Jul 27, 2023 11:20 PM Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

Jul 27, 2023 04:33 PM Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

Jul 26, 2023 07:30 AM Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Jul 19, 2023 08:30 AM Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

Jun 27, 2023 08:30 AM Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Jun 2, 2023 07:30 AM Inozyme Pharma to Present at the Jefferies Healthcare Conference

May 9, 2023 08:30 AM Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Apr 14, 2023 08:30 AM Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Apr 11, 2023 08:30 AM Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Apr 4, 2023 08:30 AM Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

Mar 22, 2023 08:30 AM Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Mar 1, 2023 08:30 AM Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

Feb 16, 2023 07:30 AM Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Feb 6, 2023 07:30 AM Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

Jan 9, 2023 08:30 AM Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

Dec 5, 2022 08:30 AM Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

Dec 1, 2022 07:30 AM Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

Nov 10, 2022 08:30 AM Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 7, 2022 07:30 AM Inozyme Pharma to Participate in Upcoming Investor Conferences

Nov 3, 2022 07:30 AM Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

Oct 31, 2022 07:30 AM Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Sep 6, 2022 07:30 AM Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 15, 2022 07:30 AM Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

Jul 26, 2022 07:30 AM Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

Jul 19, 2022 04:30 PM Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Jun 16, 2022 07:30 AM Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

Jun 7, 2022 07:30 AM Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

Jun 1, 2022 07:30 AM Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

May 10, 2022 07:30 AM Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights